INTRODUCTION
In the late 1980s, when 'innovators' first began applying noninvasive mechanical ventilation (NIV) as a potential alternative to endotracheal intubation [1] , few individuals would have thought that less than 20 years later, NIV would become a first-line intervention for certain forms of acute respiratory failure (ARF) [2] .
EPIDEMIOLOGY OF NONINVASIVE MECHANICAL VENTILATION
Surveys have found that the utilization of NIV varies greatly between hospitals and geographic regions and has been changing over time [3] . In some countries like France, NIV is very popular and its use in ICUs increased from 16 to 23% of the total ventilated patients and from 35 to 52% of patients not intubated before ICU admission between the years 1997 and 2002 [4] . Another European survey showed considerable differences in the utilization of NIV depending on the diagnosis [5 & ]. In Europe, the rate of NIV utilization in ICUs is approximately 35% of ventilated patients and much higher (60%) in Respiratory Intensive Care Units (RICUs) or Emergency Departments (EDs). In North America, NIV is begun most often in EDs with most patients transferred to ICUs or to step-down units in hospitals having such units. The percentage of initial ventilator starts varies and overlaps with that of Europe [6] [7] [8] . In certain hospitals and geographical areas, NIV appears to be underutilized [9] because of inadequate training, lack of knowledge about or experience with the technique, insufficient technical equipment and lack of funding [5 & ,6 ].
WHEN TO START NONINVASIVE MECHANICAL VENTILATION
NIV is indicated during clinical and functional signs of acute respiratory distress, in particular:
(1) Poor alveolar gas exchange (PaO 2 /FiO 2 < 200) (2) Ventilatory pump failure with hypercapnia and respiratory acidosis (PaCO 2 > 45 mmHg and pH < 735) (3) Severe dyspnea accompanied by use of accessory respiratory muscles (4) Tachypnea (with respiratory rate > 24 breaths/ min)
In the presence of these conditions, NIV should be initiated as soon as possible.
It is also important to bear in mind the conditions that rule out NIV and require intubation with no delay:
(1) Impaired neurological state (Kelly score > 4) (2) Respiratory arrest (3) Shock or in general severe cardiovascular instability (4) Excessive airway secretions (5) Facial lesions that prevent the fitting of nasal or facial masks.
CLINICAL INDICATIONS TO NONINVASIVE MECHANICAL VENTILATION
NIV may be used to treat several clinical conditions.
Hypercapnic respiratory failure and chronic obstructive pulmonary disease exacerbations
The first studies on the role of NIV in chronic obstructive pulmonary disease (COPD) patients experiencing acute hypercapnic respiratory failure (AHRF) were conducted in the late eighties [10] . Since then, several randomized controlled trials (RCTs) have shown that NIV added to standard medical treatment reducing mortality, avoiding intubation, improving dyspnea and reducing hospital length of stay in COPD patients with ARF when compared to medical management and oxygen therapy alone [2, 11, 12 ]. An RCT conducted on 236 patients showed that the NIV success was especially high in patients with mild acidosis (pH > 7.30) [13] , whereas patients with more severe acidosis did not fare equally well and were more likely to require intubation. These data point to the need for an early and accurate differentiation between patient subgroups, in order to promptly address them to the most effective treatment. A recent prospective study conducted in the UK on 9716 in-patients with COPD exacerbation and ARF managed in general clinical practice showed an overall mortality of 25% in patients receiving NIV, significantly higher than the figures reported in the RCTs [14 && ]. There are several potential explanations, including inaccurate selection of candidates for NIV, the use of NIV as a ceiling of treatment in patients with very severe disease, or substantial delays in initiating the ventilatory treatment.
Very recently other forms of AHRF not related to COPD exacerbation were retrospectively studied. NIV success was very high in acute exacerbation of pulmonary tuberculosis sequelae [15] and in chronic hereditary neuromuscular disease, but not in the acquired diseases [16] . The NIV failure rate was reported to be 32% in a population of patients with brochiectasis, and this was predicted by the presence of severe hypoxemia [17] .
Cardiogenic pulmonary edema
Treatment with continuous positive airway pressure (CPAP), practical and easy to perform also in EDs, has long been known to improve survival rate and lower the need for intubation in cardiogenic pulmonary edema (CPO) patients compared to conventional medical treatment and oxygen therapy [18] .
KEY POINTS
Noninvasive mechanical ventilation (NIV) could be considered the first-line intervention in acute respiratory failure (ARF) due to COPD exacerbations, cardiogenic pulmonary edema, pulmonary infiltrates in immunocompromised patients, and in weaning the patients recovering from a hypercapnic respiratory failure.
The use of NIV in real life has been increasing in the past few years both inside and outside the ICU.
Novel and expanding applications for NIV are postsurgical period, prevention of ARF in asta, prevention of postextubation ARF in at-risk patients, obesity hypoventilation syndrome, old and very old patients.
The timing of NIV application is critical to increase the success rate; the earlier it is started the better outcome you may get.
In hypoxemic patients conventional NIV has not produced significant improvements over CPAP in two randomized studies although it can be effective in CPO patients exhibiting hypercapnia [19] . A multicenter trial comparing oxygen therapy alone, CPAP and NIV [20] established that with NIV, the physiological improvements were faster than with oxygen alone, but without any significant effect on intubation or mortality rates. However, the very low intubation rate in this study (<3%) raises questions as to whether the patient population was comparable to that of other studies.
In a multicenter randomized trial performed in the EDs, 200 patients received either NIV or CPAP with an intubation rate of 6 and 4%, respectively. The former method accelerates the improvement of respiratory failure vs. CPAP, but did not affect primary clinical outcomes either in overall population or in subgroups of patients with hypercapnia or those with high B-type natriuretic peptide [21
Role of noninvasive mechanical ventilation in weaning and postextubation failure
According to a recent meta-analysis [22] , NIV may be used in the ICU to shorten the weaning process in stable patients recovering from hypercapnic respiratory failure (HRF) who had previously failed a spontaneous breathing trial (SBT). This approach may also reduce, compared to the standard weaning process, the mortality rate and the incidence of ventilator-associated pneumonia.
In a very recent study [23 && ] patients intubated for HRF who failed a first SBT were randomly assigned to three groups: conventional invasive weaning group, extubation followed by standard oxygen therapy or NIV. NIV was permitted as rescue therapy for both non-NIV groups if postextubation ARF occurred. Reintubation rates were 30, 37 and 32%, respectively. Weaning failure rates, including postextubation ARF, were 54, 71 and 33%, respectively (P < 0.001). Rescue NIV success rates for invasive and oxygen therapy groups were 45 and 58%, respectively. The authors concluded that NIV decreases the intubation duration and may improve the weaning results in difficult-to-wean chronic hypercapnic respiratory failure (CHRF) patients by reducing the risk of postextubation ARF.
Postextubation failure occurs in a percentage of patients above 15% [24] . Necessity for reintubation usually becomes apparent 48-72 h after extubation, and is associated with a high mortality rate, as well as a high risk for lower respiratory tract infections.
NIV has been applied to prevent extubation failure in a group of 'at-risk' patients, mainly those affected by hypercapnia, when it was shown that in this population NIV reduced, compared to standard therapy, the incidence of postextubation respiratory failure and the need for reintubation, and in one study also the overall 90-day mortality.
It was also shown that the preventive application of NIV combined with assisted coughing after extubation averted the need for reintubation and shortened the length of ICU stay, compared to patients who received 'only' standard medical therapy [25] .
The effectiveness of NIV after extubation in preventing postextubation failure in 'unselected' patients was investigated in 406 patients randomized [26 & ] to usual medical therapy and NIV. The results suggest that NIV may be of clinical advantage in the postextubation period, but only in a selected group of patients (i.e. those with hypercapnia).
When NIV was used to treat, rather than to prevent postextubation failure, a recent retrospective analysis showed that in a cardio-surgical population, both CPAP and NIV were useful in avoiding reintubation and decreasing the rate of pulmonary infections, compared to those patients reintubated immediately, after a deterioration of PaO 2 /FiO 2 without hypercapnia [27].
Respiratory failure in immunocompromised patients
Immunocompromised patients, particularly exposed to infectious risk related to endotracheal intubation and invasive ventilation, can potentially benefit significantly from NIV. In fact NIV, especially when applied early, can significantly improve the conditions of these patients, reducing intubation and mortality, and can even be administered outside the ICU, so as to avoid the exposure to the ICU environment. In 2011 Gristina et al. 
Role of noninvasive mechanical ventilation in hypoxic patients
One of the major confounders of these studies was the marked variability of the case-mix; patients with different underlying disorders and pathophysiologic pathways were included under the same generic definition of having hypoxemia.
A study [29] performed in three European ICUs having expertise with NIV clarifies the 'real life' use of NIV in these conditions. It was shown that 'only' 16.5% of the patients admitted with ARDS may be successfully treated with this technique. In a 2-year period, 479 patients were admitted and the large majority (69%) were already intubated at admission, so that only 147 were eligible for this study. NIV improved gas exchange and avoided intubation in 54% of this subset of patients, leading to an overall success rate below 20%. This was associated with less ventilator-associated pneumonia and lower ICU mortality rate (6 vs. 53%). Similar data were obtained in a small RCT performed in patients not requiring immediate intubation and randomized to oxygen therapy or NIV. Eight of 10 patients in the former group required intubation vs. six of 10 in the latter [30] .
The timing of application is extremely important. Cosentini et al. [31 & ] have shown that the precox application with CPAP using the helmet was able to rapidly improve oxygenation, compared to oxygen therapy alone, in patients with community-acquired pneumonia and ARF in an initial phase (i.e. PaO 2 / FiO 2 > 210 < 285). Similar results were obtained using early intermittent NIV for acute chest syndrome in patients with sickle cell disease [32] .
Quite recently NIV was also proposed to treat an exacerbation of idiopathic pulmonary fibrosis. Two studies showed that NIV may be considered a valid option to treat these episodes, despite the fact that final outcomes were usually very poor [33, 34] .
Postsurgical period
Major abdominal and thoracic surgeries are often complicated by hypoxemia and ARF during the postoperative period. Pulmonary atelectasis is a frequent complication and may predispose to pneumonia. Randomized studies have shown that CPAP decreases atelectasis and prevents pneumonia more effectively than standard therapy after upper abdominal surgery [35] and that NIV significantly improves gas exchange and pulmonary function abnormalities after other procedures including thoracic [36] , cardiac [37] and vascular surgeries [38] , liver resection [39 & ] and thyroidectomy [40] . These studies support the use of CPAP or NIV in the postoperative setting, but more are needed before specific recommendations can be made.
Noninvasive mechanical ventilation and pandemics
This application of NIV has generated debate. On the basis of the Toronto experience in which a number of caregivers contracted SARS when a patient was intubated following failure of NIV, this technique was discouraged for such patients [41] . However, two subsequent observational studies from China [42, 43] found no evidence of viral spread to caregivers who took appropriate precautions. More recently NIV was also used in the treatment of ARF due to H1N1 infection. In a Chinese study 23 of 64 patients were ventilated initially with NIV and only three of them required intubation, whereas in a smaller Spanish study NIV failure was 50% [44, 45] . In the event of a pandemic, ventilator resources are likely to be severely strained, and NIV may offer a means of supporting some of the afflicted. However, some consider NIV contraindicated in respiratory failure from communicable respiratory airborne diseases unless it is used inside a negative pressure isolation room and strict precautions are taken. Interestingly it has been shown that NIV produces droplets of 10 mm size and due to their large mass, most fall out on the local surfaces within 1 m, so that infection control measures designed to limit aerosol spread may have less relevance than the 'usual' measures of protection that every caregiver should adopt [46
Emerging applications
Based mainly on the results of RCTs, NIV is the preferred ventilatory modality in certain previously described conditions. Observational studies suggest that NIV may also be used to treat ARF associated with other conditions.
Few studies have assessed the use of NIV during a severe, non life-threatening asthma attack prior to the development of ARF.
The most recent study [47 & ] showed that the addition of NIV accelerated the improvement in lung function, decreased bronchodilator requirement and shortened the ICU and hospital stay. A trial of NIV can be considered to prevent the occurrence of ARF in asthmatic patients who fail to respond adequately to initial bronchodilator therapy.
With increased life expectancy, living to an advanced age is common.
Although it has been demonstrated that the inhospital mortality is similar in old and younger patients admitted to ICU [48], older patients usually receive less invasive and costly hospital care, even after adjustment for the severity of their illness.
In a prospective, multicenter, randomized study, the authors compared the effect of NIV to that of standard medical therapy in reducing the rate of meeting the intubation criteria in patients older than 75 with AHRF. NIV decreased the rate of meeting these criteria and the mortality rate, so that it was concluded that NIV should be offered as an alternative to patients considered poor candidates for intubation and those with a DNI order [49 && ]. Similar results were also observed in two observational studies performed in patients with a similar age [50, 51] .
CONCLUSION
In summary, the past two decades have witnessed a dramatic increase in the use of NIV, which at present has become a clear first-line treatment in the management of ARF in conditions as diverse as COPD, cardiogenic pulmonary edema and, in many instances, in immunocompromised patients. Moreover, NIV is no longer confined to the ICU, but in expert hands, it has crossed ever more often into the regular ward, thus broadening the spectrum of options available for the treatment of respiratory failure. Current research is focusing on improving the quality and safety of the devices and establishing new ventilatory modes in order to extend even further the indications to NIV as well as its rate of success. 
